Potassium isopropenyltrifluoroborate
Product Information
Molecular Formula
C3H5BF3.K
Molecular Weight
147.975
Description
Potassium isopropenyltrifluoroborate is a highly versatile compound that finds extensive usage in the biomedical industry. Its main function lies in serving as a reagent to enable a plethora of organic reactions, including cross-coupling reactions and palladium catalysis. Notably, this reagent assumes a pivotal role in synthesizing pharmaceutical compounds, agrochemicals, and fine chemicals.
Synonyms
Potassium isopropenyltrifluoroborate
IUPAC Name
potassiumtrifluoro(prop-1-en-2-yl)boranuide
SMILES
[B-](C(=C)C)(F)(F)F.[K+]
InChI
InChI=1S/C3H5BF3.K/c1-3(2)4(5,6)7/h1H2,2H3/q-1+1
InChI Key
QKBZHQPFHGKCOX-UHFFFAOYSA-N
Melting Point
274-280 °C
Flash Point
Not applicable
Purity
97%
Safety Information
Hazards
H314
Precautionary Statement
P280 - P305 + P351 + P338 - P310
Computed Properties
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
4
Rotatable Bond Count
0
Exact Mass
148.0073463 g/mol
Monoisotopic Mass
148.0073463 g/mol
Topological Polar Surface Area
0Ų
Heavy Atom Count
8
Formal Charge
0
Complexity
87
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
2
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| WO-2021257804-A1 | Thyromimetics | 2020-06-17 |
| WO-2021239643-A1 | Benzylamine derivatives as ddrs inhibitors | 2020-05-25 |
| WO-2021222353-A1 | Macrocyclic inhibitors of peptidylarginine deiminases | 2020-04-30 |
| WO-2021203028-A1 | 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd) | 2020-04-03 |
| WO-2021108549-A1 | Novel thyromimetics | 2019-11-29 |
| WO-2021086833-A1 | Small molecule inhibitors of kras g12c mutant | 2019-10-28 |
| WO-2021080929-A1 | N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | 2019-10-25 |
| WO-2021062245-A1 | Pyridone compounds and methods of use in the modulation of a protein kinase | 2019-09-26 |
| WO-2020224568-A1 | Cdk inhibitors | 2019-05-05 |
| AU-2020269469-A1 | CDK inhibitors | 2019-05-05 |
